Free tool
FAERS Monitor: Firazyr
Last checked: Nov 20, 2026FDA FAERS (openFDA) last updated: Oct 28, 2026Methods & limitations
Reports naming NDA 022150 or its brand name (Firazyr, Icatibant Acetate). Reports on generic versions are filed under their own applications.
Reports
6,011
Serious
4,052
67% of reports
Hospitalization
2,349
Death reported
155
Any cause; not necessarily from the drug
Most reported reactions
MedDRA preferred terms.
- hereditary angioedema2,634
- drug ineffective504
- product dose omission issue451
- weight decreased415
- weight increased379
- injection site pain307
- off label use277
- product use issue275
- inappropriate schedule of product administration243
- headache234
- stress217
- condition aggravated203
- malaise200
- covid-19191
- nausea182
Reports by year received
View as table
| Year | Reports |
|---|---|
| 2010 | 1 |
| 2011 | 4 |
| 2012 | 46 |
| 2013 | 219 |
| 2014 | 215 |
| 2015 | 384 |
| 2016 | 400 |
| 2017 | 296 |
| 2018 | 622 |
| 2019 | 586 |
| 2020 | 406 |
| 2021 | 422 |
| 2022 | 456 |
| 2023 | 504 |
| 2024 | 442 |
| 2025 | 503 |
| 2026 | 505 |
Disproportionality screen
Proportional reporting ratio (PRR): how much more often each reaction appears in this drug's reports than in the other 21,048,148 FAERS reports. Flagged when PRR is at least 2, chi-squared at least 4 and there are 3 or more reports (Evans criteria). A screening statistic only.
| Reaction | Reports | PRR | 95% CI lower | Chi-squared |
|---|---|---|---|---|
| hereditary angioedemaSignal | 2,634 | 1137.5 | 1097.4 | 2,257,908 |
| stressSignal | 217 | 10.6 | 9.3 | 1,870 |
| weight increasedSignal | 379 | 5.9 | 5.4 | 1,563 |
| product dose omission issueSignal | 451 | 5.4 | 4.9 | 1,621 |
| weight decreasedSignal | 415 | 5.2 | 4.7 | 1,424 |
| product use issueSignal | 275 | 5.1 | 4.6 | 916 |
| inappropriate schedule of product administrationSignal | 243 | 4.7 | 4.2 | 715 |
| covid-19Signal | 191 | 3.8 | 3.3 | 396 |
| injection site painSignal | 307 | 3.5 | 3.1 | 555 |
| condition aggravatedSignal | 203 | 2.3 | 2.0 | 156 |
| malaise | 200 | 1.6 | 1.4 | 45 |
| drug ineffective | 504 | 1.3 | 1.2 | 46 |
| headache | 234 | 1.3 | 1.2 | 17 |
| off label use | 277 | 1.1 | 1.0 | 3 |
| nausea | 182 | 0.8 | 0.7 | 9 |
A high PRR for a reaction that is also the condition being treated (for example "disease progression" for a cancer drug) is expected and is not a safety signal.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.